Press Release | Newsroom | Medtronic | HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast

Press Release

Printer Friendly Version View printer-friendly version
<< Back
HeartWare Schedules First Quarter 2016 Financial Results Conference Call And Webcast

FRAMINGHAM, Mass., April 19, 2016 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call and webcast to discuss its financial results for the three months ended March 31, 2016, on Wednesday, May 4, 2016 at 8:00 a.m. ET.  The company plans to release the financial results prior to the conference call and webcast, during which management will discuss the company's financial results, highlights from the first quarter and business outlook.  

The conference call may be accessed by dialing 1-877-407-0789 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-201-689-8562.

The live webcast will be available from the Investors section of the company's website (  A replay will be available through the same link immediately following completion of the call.

A copy of the news release announcing the financial results and related information will be available on the company's website,

About HeartWare International
HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare HVAD System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat more than 10,000 patients in 47 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit  

Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864

HeartWare International, Inc.

Logo -


To view the original version on PR Newswire, visit:

SOURCE HeartWare International, Inc.